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Abstract 
Nanoparticles of poorly water-soluble drugs were prepared in suspension via antisolvent 
precipitation in order to improve their dissolution behaviour.  Insoluble, surface-functionalized, 
micron-range, clay carrier particles were employed for the dual purpose of stabilizing the 
nanoparticles in suspended state, and facilitating their unhindered isolation to solid state; often a 15 
challenging step in nanoparticle production. The carrier particles, which were functionalized with an 
optimal level of cationic polymer (protamine), attracted negatively-charged nanoparticles to their 
surface as a uniform and segregated nanoparticle layer, at drug loadings up to 9% w/w. By using 
carrier particles to stabilise the nanoparticles on their surface, the traditionally used solubilised 
nanosuspension stabilisers could be eliminated, thus avoiding time-consuming stabiliser screening 20 
tests. The carrier particle system facilitated stabilisation of nanoparticles in suspension, isolation of 
nanoparticles to the solid state via filtration, and preservation of fast nanoparticle-induced 
dissolution rates of the dried nanoparticle-carrier composites, indicating preservation of their high 
surface area during drying. The process was validated with two poorly water-soluble BCS Class II 
drugs, fenofibrate and mefenamic acid, both of which demonstrated negative surface charge in 25 
aqueous suspension. 
Keywords 
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1. Introduction 
Many potential active pharmaceutical ingredient (API) candidates have poor water solubility and 
slow dissolution rates in vivo, leading to limited bioavailability and failure to reach the market [1, 2]. 
Nano-sizing of pharmaceutical particles to < 1 µm provides an effective means of accelerating their 
dissolution rate by significantly enhancing their surface area [3, 4]. Such nanoparticles can be 5 
prepared in suspension through a variety of crystallization or size reduction approaches, but their 
isolation from suspension into the dried state is a research area that has been relatively neglected. 
Drug nanoparticles in suspended state have a predisposition to physical and chemical instability and 
have a tendency to grow or aggregate to reduce their free energy. Dissolved additives are generally 
required to stabilize the nanoparticle size in suspension, requiring rigorous additive-screening 10 
approaches. For long term stabilization and for convenience during oral administration, 
nanoparticles are often isolated into the solid state for incorporation into solid dosage forms such as 
tablets. Conventional nanoparticle isolation techniques (eg. freeze-drying [5-7], spray-drying [1, 6, 8, 
9] and centrifugation [10]) are quite complex processes which can induce nanoparticle aggregation 
and consequential reduction in dissolution rates compared to suspended nanoparticles.  15 
Some alternative nanoparticle isolation strategies have been proposed in recent years, eg. 
nanoparticle coating onto water-soluble carriers in a fluidized bed [11],  reversible salt- flocculation 
and filtration [12], and matrix formers for aggregation prevention during spray drying [8]. In 2014, 
Khan  et al. showed that insoluble carrier particles composed of dibasic calcium phosphate could be 
used to recover nanocrystals of ibuprofen and glibenclamide from suspension by filtration [13]. 20 
Filtration is a desirable particle separation technique at industrial scale, but can become problematic 
when dealing with small micron or nanosized particles. Adsorption of nanoparticles to relatively 
large carrier materials can facilitate their filtration. The concept of using carrier particles has had 
widespread application in the preparation of dry-powder inhaler formulations [14-16] and in 
ordered mixing [17] where sugars have regularly been employed as carrier particles. The report by 25 
Khan et al. presented the first and, to our knowledge, only application for carrier mediated isolation 
of drug nanocrystals from suspension. However, the process was notably limited by a low maximum 
drug loading of 0.35%, restricting its application to high potency drugs  [13]. In addition, prior 
knowledge of drug-specific, soluble stabilizers was required, which was the focus of an earlier study 
by the group [10]. 30 
This work presents a novel one-step, carrier-mediated method for preparing, stabilizing and isolating 
fast-dissolving, solid-state drug nanoparticles of poorly water-soluble BCS Class II drugs, fenofibrate 
3 
 
and mefenamic acid. Fenofibrate and mefenamic acid were chosen as model compounds for this 
study on the basis that nanosizing has been previously shown to enhance their dissolution behaviour 
[8, 18-22]. Previously, our group prepared and stabilized nanosuspensions of fenofibrate [18], and 
mefenamic acid [22] by antisolvent precipitation in the presence of dissolved polymer and 
surfactant-based additives. In both cases, the dissolved stabilizers provided only short-term 5 
stabilisation in suspension and were incapable of stabilising the nanoparticles during isolation and 
drying, causing them to forego their nanoparticle-induced dissolution enhancement.  In the present 
work, the precipitated nanoparticles were captured from suspension and stabilized on the surface of 
a functionalized clay carrier excipient. Carrier bound nanoparticles were isolated from suspension by 
filtration, and their fast nanoparticle-induced dissolution rates were preserved during the isolation 10 
and drying processes. The previously used optimum additives for each drug system were omitted in 
the presence of carrier particles, as their function was made redundant. Nanoparticle/carrier 
composites were prepared with a drug loading of up to 9%, for further use in the final drug 
formulation. 
The carrier (montmorillonite, MMT) is an insoluble, negatively-charged aluminosilicate clay with high 15 
ion-exchange capacity. Its surface functionalization agent (protamine, PA) is a positively-charged 
cationic polymer which can easily adsorb to the clay following an ion-exchange process [23, 24] and 
attract negatively-charged drug nanoparticles to its surface. Both MMT and PA have FDA approval as 
inactive ingredients [25] . 
 20 
2. Material and Methods                      
 
2.1 . Materials  
Fenofibrate (as received, 99.7% purity) and fenofibrate choline salt (crude) were generously gifted 
from Abbvie Laboratories. Converted fenofibrate (FF) was prepared from the salt form by the 25 
procedure outlined in Supplementary Information. Ethanol (99.8%) was purchased from Merck 
Millipore. Mefenamic acid (MEF, Form I, >98%), N, N-dimethylacetamide (DMA, >99.9%), 
montmorillonite K10 (MMT), protamine sulphate salt from salmon (PA, amorphous, approx. 5.1 
kDa), hydrochloric acid, Tween-80, isopropanol (≥ 99.9%), thionyl chloride (≥ 99.9%) and potassium 
carbonate (≥ 99%) were purchased from Sigma Aldrich. Potassium dihydrogen phosphate and 30 
disodium hydrogen phosphate were purchased from VWR International. TriCor tablets (commercial 
nanoformulation of FF) were purchased from Abbott. Ponstan capsules (commercial micron 
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formulation of MEF) were purchased from Chemidex Pharma Ltd. Distilled water was used for 
sample preparations. 
2.2 . Functionalization of the Montmorillonite Surface  
Protamine sulphate salt was dissolved in water at concentrations ranging from 0.5 – 500 mg/10 mL. 
Montmorillonite clay (0.4 g – 1 g) was added to the protamine solution, and agitated at 25°C for > 2 5 
hrs. The surface coverage of protamine on montmorillonite was altered by increasing the ratio of 
protamine to MMT (2 - 1000 mg PA/g MMT) to generate an adsorption isotherm. The saturation 
limit of protamine on MMT was identified from the adsorption isotherm as the point at which no 
more protamine adsorbed, and was verified by an increasing protamine concentration in equilibrium 
solution. PA-MMT samples were equilibrated for > 2 hrs, before vacuum-filtering using Whatman 10 
filter paper 50 (2.7 µm pore, 35 mm cross-section). The concentration of protamine remaining in the 
filtrate was measured by UV-visible spectroscopy (Shimadzu UV-1280) at a wavelength of 200 nm 
(lower detection limit 0.0025 mg/mL) and served as an indication of the loading of protamine to the 
MMT. The calibration curve for protamine is shown in Supplementary Information (Fig. S1).  
2.3. Zeta Potential Determination 15 
Zeta potential measurments were conducted on a Malvern Zetasizer Nano ZSP system. Zeta 
potential was determined from the electrophoretic mobility using the Smoluchowski approximation. 
The precipitated samples (without dilution) were filled into a folded capillary cell and equilibrated at 
25 °C for 120 s before measurement. Three measurements were taken per run and each sample was 
run twice. The average value and the standard deviation between repeated measurements were 20 
reported. 
2.4. Synthesis of Nanoparticles and their Loading onto Carrier Particles.   
Suspended nanoparticles of both fenofibrate (FF) and mefenamic acid (MEF) were generated by 
antisolvent precipitation. An organic solution of FF in ethanol (1 mL, 50 mg/mL) was quickly 
introduced by Eppendorf pipet to 10 mL antisolvent containing (a) water, (b) an MMT suspension in 25 
water (50 mg/mL, equilibrated for >2 hrs) or (c) a protamine-modified MMT suspension in water (50 
mg/mL, 4.6 – 189.9 mg PA/g MMT, equilibrated for >2 hrs). Solutions/suspensions were maintained 
at 25°C under rapid agitation (800 rpm) throughout the precipitation process. For standard 
experiments, particles were aged for 1 min before drying. Aging time refers to the time period from 
precipitation to isolation during which the particles are held in suspension.  1 min aging time before 30 
drying was selected since this time was short enough to ensure the nanoparticle size was preserved, 
but long enough to allow for reproducible and consistent sampling. Exceptions to this aging time 
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were made for stability testing. Two additional experiments were conducted at (i) 100 mL scale and 
(ii) where the protamine-modified MMT suspension (50 mg/mL, 4.6 mg PA/g MMT, equilibrated for 
>2 hrs) was added to the water-precipitated fenofibrate suspension at 20 s after precipitation, and 
aged for an additional 1 min before drying. FF nanoparticles from preparation (a) were isolated by 
freeze-drying on a Dura-Dry Microprocessor Control freeze-dryer at <20 Pa for 48 hrs after flash-5 
freezing in liquid nitrogen.  Particles from all other preparations were isolated by vacuum-filtration 
(Mini diaphragm vacuum pump, VP 86) using Whatman filter paper 50 (2.7 µm pore, 35 mm cross 
section), and washed with 2 mL water. Filter cakes were dried under vacuum (<20 Pa) for 24 hrs and 
stored at standard ambient temperature before analysis.  
Suspended nanoparticles of MEF were prepared and isolated according to the procedure outlined by 10 
Bodnar et al. [22] with slight modification. An organic solution of MEF in DMA (0.5 mL, 40 mg/mL, 25 
°C) was quickly introduced by Eppendorf pipet to a 9.5 mL aqueous solution of docusate sodium salt 
(0.53 mg/mL, 5 °C) antisolvent under rapid agitation (1200 rpm). After 1 min aging, free 
nanoparticles were isolated from suspension by direct filtration with a nylon membrane (0.2 µm). To 
prepare nanoparticle-carrier composites, MEF was precipitated under the same conditions but with 15 
the replacement of the docusate sodium stabilizer in the antisolvent for protamine-modified MMT 
(42 mg/mL MMT in water, 4.6 mg PA/g MMT).  After 1 min aging, particles were vacuum filtered in 
the same way as the FF-carrier composites.   
Nanoparticle attachment to the carrier particles (ie. drug loading) was indirectly monitored by 
measuring the drug content remaining in the filtrate after filtration (2.7 µm filter pore), and using 20 
mass balance to calculate the amount of drug retained by the filter, thus indicating nanoparticle 
attachment to the carrier. Unattached nanoparticles could pass through the filter to produce a milky 
filtrate, while carrier-attached nanoparticles could not, resulting in a clear filtrate. An aliquot of the 
filtrate was diluted by a factor of 10 in methanol and equilibrated for 24 hrs to dissolve any drug 
particles present before measuring the dissolved drug concentration using a Shimadzu UV-1280 UV-25 
visible spectrophotomer at a wavelength of 289 nm (lower detection limit 0.003 mg/mL). The 
calibration curve for fenofibrate in a 9:1 methanol:water solution is shown in Supplementary 
Information (Fig. S2).  
Centrifugation was further used to distinguish whether the nanoparticles adsorbed to the PA-
modified MMT or if it simply served as a filtration aid to remove the nanoparticles from suspension. 30 
Samples containing free FF nanoparticles, a PA-MMT control, and a FF-PA-MMT composite were 
aged for 0.5 min before centrifuging at a speed of 5000 rpm for 2 min. The supernatant was 
decanted into a separate vial and the FF content in the supernatant was measured by UV-visible 
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spectroscopy after dissolving a portion in methanol and leaving to equilibrate for 24 hrs. On knowing 
the drug content in the supernatant, a mass balance was used to estimate the % of drug which 
sedimented. This was used as an indicator of the % of drug available which adsorbed to the PA-MMT 
carrier from suspension.  
2.5. Dissolution Testing 5 
The dissolution medium for FF samples consisted of a 0.1 M HCl solution containing 0.4% w/v 
Tween-80 at 42°C. The dissolution medium for MEF samples consisted of a 0.05 M pH 7.4 phosphate 
buffer with 0.05% w/v Tween-80 at 37°C. Dissolution tests were carried out in sink conditions by 
adding a sample (powder or suspension) containing 12.5 mg API to 450 mL dissolution medium 
(0.0278 mg/mL) under agitation of 400 rpm. TriCor tablets (commercial FF) were ground to a powder 10 
by pestle and mortar for 2 min prior to dissolution testing. The powder contained in Ponstan 
capsules (commercial MEF) was extracted from the capsules for use in dissolution testing. After 
sample addition, 4 mL aliquots were taken at regular intervals from the bulk solution in preheated 
(45°C) plastic syringes and filtered through preheated (45°C) PTFE 0.2 µm syringe filters. The 
dissolved drug concentration was measured by UV-visible spectroscopy (Shimadzu UV-1280) at a 15 
wavelength of 289 nm for both FF and MEF (lower detection limit 0.003 mg/mL). The calibration 
curves for FF and MEF in their respective dissolution media are shown in Supplementary Information 
(Fig. S3). The dissolution medium was not replaced after each sampling. This work presents the first 
10 minutes of dissolution tests, but all dissolution profiles reached approx. 100% dissolved within 5 
hours. Dissolution tests were carried out at least in duplicate.  20 
2.6. Particle Size Analysis 
Particle size measurements were performed by laser diffraction using a Malvern Mastersizer 3000, 
with water as the dispersion medium. In cases where the particle size was not stable (Prep (a) in 
section 2.4), HPMC and SDS were added to the water dispersant at a concentration of 0.038 mg/mL 
each to minimize variation between consecutive measurements. Precipitated drug suspensions were 25 
diluted by a factor of 5 with water prior to their introduction to the measurement vessel. An MMT 
control was treated by the conditions used during antisolvent precipitation before measuring its 
particles size. An obscuration rate of 7-10%, a stir rate of 2300 rpm, a 1 min premeasurement delay 
(including 20 sec with 5% sonication power) were the conditions used during all size measurements. 
A refractive index of 1.55 and an absorption index of 0.01 were used for FF measurements. A 30 
refractive index of 1.55 and an absorption index of 0.1 were used for MMT measurements. Four 
measurements were taken per run and each sample was run twice. The D50 diameter was reported 
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for each size distribution and averaged across all measurements. The standard deviation of repeated 
measurements was also reported. 
2.7. X-ray Powder Diffraction 
X-ray diffraction patterns of the powders were recorded using a PANalytical Empyrean 
diffractometer in transmission mode, using Ni filtered CuKα radiation (λ=1.54 Å) at 40 kV and 40 mA. 5 
The XRD data was recorded in the range of 20.5–23.0 °2θ for FF samples and the range 14.5-16.5 °2θ 
for MEF samples. 
 
3. Results 
3.1. Solid-State Drug-Carrier Composites.  10 
Drug nanoparticles of FF and MEF which were precipitated from a supersaturated solution, captured 
by a functionalized carrier (PA-MMT), filtered and vacuum dried maintained a dissolution rate which 
was equivalent to that of the suspended (and stabilized) nanoparticles (300-400 nm) reported 
previously by our group [18, 22], Fig. 1.  The solid-state particles prepared in this way preserved their 
fast, nanoparticle-induced dissolution rates during isolation and drying, unlike when freeze-drying or 15 
direct filtration (0.2 µm) were used, Fig. 1. The PA-MMT carrier alone was able to stabilze the 
nanoparticle size and surface area (as indicated by dissolution rates) of both FF (9.1% loading) and 
MEF (4.8% loading) during drying, without the need for the drug-specific dissolved stabilizers which 
were previously reported for each system [18, 22]. The fast dissolution rates achieved by the dried 
drug-carrier composites were comparable to or faster than that of their respective dry-powder 20 
commercial drug formulations (TriCor [nano] and Ponstan [micron]), which were prepared by milling, Fig. 
1. Extended dissolution profiles are shown in Supplementary Information (Fig. S4), highlighting that 
all samples reached approx. 100% dissolved within 5 hrs.  
 
8 
 
Fig. 1. Dissolution profiles of (a) FF and (b) MEF comparing dissolution profiles of the commercial 
formulations, and precipitated material in suspension and after drying (1 min aging). Dried particles, 
in the absence and presence of carrier particles (9.1% FF loading, 4.8% MEF loading) were compared.  
Additional tests with the FF system showed that the fast dissolution rate of the dried nanoparticle-
carrier composites was maintained when the carrier was added 20 s after, versus before 5 
precipitation, when the aging time in suspension was increased from 1 min to 24 hours, or when the 
process was scaled up from 10 mL to 100 mL, Fig. 2. Furthermore, nanoparticles in the nanoparticle-
carrier composites were stable in the dried state over a monitored period of 10 weeks (Fig. S5, 
Supplementary Information)  
 10 
Fig. 2. Dissolution profiles of dried FF composites highlighting the influence of variation from 
standard conditions (which are: carrier present during precipitation, 1 min aging, 10 mL scale)   
Particle sizes of the drug particles in the drug-carrier composites could not be measured directly by 
laser diffraction due to their attachment to the larger carrier particles. Drug particles were 
designated as ‘nano’ particles on the combined basis of their known nanosize in suspension (without 15 
carrier particles) and their preserved fast dissolution rates when attached to the carrier particles. 
Although highly unstable,  nanoparticles of FF (D50: 0.75±0.09 µm, Fig. 3) and MEF (D50: 0.84±0.05 
µm [22]) existed in suspension at short aging times following their precipitation from water alone.  
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Fig. 3. Particle size distribution of FF precipitated in pure water (no carrier, 1 min aging time)  
Similarly, crystallinity of the drug nanoparticles in the drug-carrier composites could not be proven 
by XRD, solid state NMR or FTIR due to the low drug content compared to the carrier content (9% 
drug content). Therefore, nanoparticles in the dried nanoparticle-carrier composites were 5 
designated as ‘crystalline’ on the combined basis of their known crystallinity when no carrier was 
present (Fig. 4), their similar dissolution rates regardless of whether the carrier was present during 
or added shortly after precipitation (Fig. 2), and based on the diffraction peaks (albeit low intensity) 
obtained from nanoparticles in the nanoparticle-carrier composites as shown in Fig. 4.  
 10 
Fig. 4. X-ray diffraction patterns for (a) FF and (b) MEF, comparing commercial formulations and 
precipitated material after drying (1 min aging time) 
3.2. Nanoparticle Attachment to the Carrier.  
Attachment of the suspended drug nanoparticles to the PA-MMT carrier (average size: 28.0 ± 1.3 
µm, Fig.  S6 Supplementary Information) was confirmed by the inability of the carrier-bound FF 15 
nanoparticles (0.75 µm) to pass through a 2.7 µm filter, as indicated by a clear FF-free filtrate 
(containing <0.5% FF). The filtration process was fast, taking < 0.5 min for the mother liquor (11 mL) 
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to pass through the filter. In comparison, control samples confirmed that >80% of free nanoparticles, 
precipitated from water or from a PA solution passed through the 2.7 µm filter when no carrier was 
present (milky filtrate). A schematic of the method used to screen for nanoparticle attachment to 
the clay is shown in Fig. 5.  
 5 
Fig. 5. A filtration test used to indicate nanoparticle adsorption to the carrier. (a) No carrier present, 
(b) no attachment to the carrier and (c) attachment of nanoparticles to the carrier.  
Centrifugation further probed whether the PA-MMT carrier adsorbed the FF nanocrystals to its 
surface or just served as a filtration aid to separate the nanocrystals from suspension during 
filtration. Centrifugation allowed the sedimentation ability of the free nanocrystals versus the 10 
carrier-attached nanocrystals to be assessed. A control sample of PA-MMT, treated by antisolvent 
conditions, sedimented during centrifugation. A second control of free FF nanoparticles in 
suspension only partially sedimented (30%) under the same centrifugation conditions, leaving a 
milky haze in the supernatant. However, in the presence of the PA-MMT carrier, 98% sedimentation 
of the FF nanocrystals occurred, giving additional indication of their adsorption to the carrier.  15 
3.3. Role of the PA Modifier. 
Free FF nanocrystals (-25.3±0.9 mV, Fig. 6), free MEF nanocrysals (-35.3±1.3 mV [22]) and 
unmodified MMT carrier particles (-26.9±1.2 mV, Fig. 6) all possess a negative electrical charge in 
aqueous media. The surface charge of the MMT was modified from negative to positive by the 
adsorption of protamine, a cationic protein. Fig. 6 shows that the zetapotential of MMT in water 20 
changed from -26.9 to -6.1 to +14.8 mV as the surface coating of PA increased from 0 to 4.6 to its 
saturation value of 200 mg PA/g MMT. 
11 
 
 
Fig. 6. Zeta potential distributions of aqueous suspensions of FF nanoparticles (-25.3 mV), un-
functionalized MMT (-26.9 mV), sparsely PA-functionalized MMT (-6.1 mV, 4.6 mg PA/g MMT) and 
PA-saturated MMT (+14.8 mV, 200 mg PA/g MMT) 
The adsorption isotherm for PA onto MMT followed a non-linear Langmuir-type increase in adsorbed 5 
protamine which tended towards its maximum (surface-saturated) value of 200 mg/g MMT, Fig. 7a. 
The zeta potential of the carrier was dependent on the coating density of protamine on the MMT 
(mg PA/g MMT), and was easily tuned to between -26.9 mV and +14.8 mV by varying the PA 
coverage, Fig. 7b.  A sparse coating of PA increased the zeta potential significantly.  
 10 
Fig. 7. (a) Adsorption isotherm for PA onto MMT and (b) the effect of adsorbed PA on zeta potential 
of PA-MMT 
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Both the nanoparticle loading and the PA loading on the carrier had a bearing on dissolution rates of 
the dried material, Fig. 8. For the FF system, the maximum drug loading at which nanoparticle-
induced fast dissolution rates were preserved in the dried form was 4.8% w/w when no PA-
functionalization was present. However, by introducing sparse PA-functionalization and by 
controlling its coverage on the MMT (4.6 mg/g MMT), the maximum drug loading at which the fast 5 
dissolution rate was preserved was increased to 9.1% w/w. Further increase in the PA-coverage on 
MMT towards its saturation point (200 mg/g MMT) had a negative influence on the dissolution rate, 
Fig. 8. Therefore, a sparse PA coverage was required for optimum dissolution at high drug loading. 
For the MEF system, 4.8% w/w was found to be the maximum loading on sparsely PA-functionalised 
MMT at which the dissolution rate of the dried material was comparable to the nanoparticles in 10 
suspension. Dissolution was marginally slower at the higher loading of 9.1% w/w (Fig. S7, 
Supplementary Information). 
For both the FF and MEF systems, the sparse PA coating on the MMT increased the speed of 
filtration; an important consideration in terms of scalability. Filtration of FF-PA-MMT composites 
(9.1% loading) was 10 times faster than filtration of FF -MMT composites at 10 mL antisolvent scale 15 
(0.5 min vs 5 min), while filtration of MEF-PA-MMT composites (4.8% loading) was 6 times faster 
than MEF-MMT composites (1.2 min vs 7.5 min).  
 
Fig. 8. Dissolution profiles of FF from dried (a) FF-MMT composites at various drug loadings and (b) 
FF-PA-MMT composites at various PA coverages 20 
 
4. Discussion     
In this work, BCS Class II drugs were formulated into fast-dissolving, solid-state nanoparticle 
composites using a simple one-step approach. Nanoparticles of fenofibrate and mefenamic acid 
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were precipitated in suspension in the presence of an insoluble excipient (a functionalized clay 
carrier) which enabled stabilization, fast filtration, drying, and fast dissolution of the surface-
adsorbed nanoparticles. Adsorption of nanoparticles to the carrier was demonstrated both by 
filtration and centrifugation techniques and the nanoparticles were found to maintain their 
crystalline form when bound to the carrier. Free nanoparticles of FF and MEF in suspension were 5 
previously found to be highly unstable, particularly so in the absence of dissolved stabilizers  [18, 
22]. This work demonstrated prolonged stabilization of the nanoparticles in suspension (over 24 hrs, 
Fig. 2) once bound to the functionalized carrier, without the need for the previously reported 
dissolved stabilizer systems which were identified on the basis of a laborious trial and error 
stabilizer-screening approach [18, 22]. The prolonged stabilization in the suspended state introduced 10 
flexibility to the isolation timeline. The carrier-bound nanoparticles were stable during their isolation 
(ie. by filtration) and drying stages, as demonstrated by the preservation of fast nanoparticle-
induced dissolution rates of the dried material. This result can be compared to nanoparticles isolated 
by freeze-drying or by direct filtration with a nano-pore filter; two isolation approaches which 
contributed to reduced dissolution rates, Fig. 1. The nanoparticles in the dried nanoparticle-carrier 15 
composites yielded dissolution behaviour equivalent to that of the suspended nanoparticles, and 
equivalent to or better than those of the commercial formulations (prepared by milling). 
Furthermore, the use of relatively large carrier particles (~28 µm) facilitated an exchange of more 
complex, but frequently used nanoparticle isolation methods (eg. spray-drying or freeze-drying) for 
the simple filtration method. An additional advantage of the carrier approach is the incorporation of 20 
the carrier as an excipient at the particle formation step (at drug concentration up to 9%) which 
bridges the gap between primary and secondary manufacturing, while simultaneously eliminating 
API-excipient segregation issues.  
The surface of montmorillonite clay contains segregated regions of hydrophobicity and charge-
induced hydrophilicity. Siloxane (≡Si-O-Si≡) units cover much of its exposed surface, giving the 25 
material a hydrophobic nature due to strong bonding interactions between silicon and oxygen atoms 
[26]. However, isomorphous substitution of selected surface atoms (eg. Si 4+ by Al 3+) provides diffuse 
regions/patches of permanent (hydrophilic) negative surface charge [23, 27-29], Fig. 9. Negative 
charges are balanced by adsorption of loosely-bound exchangeable inorganic counterions (eg. Na+, 
K+), giving the material high ion exchange capacity. In the presence of water, the counterions 30 
migrate from the surface and gain a hydration layer which introduces the regional hydrophilic 
environment between patches of hydrophobic surface [28], Fig. 9. 
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Fig. 9. Graphic description of the MMT surface in the unhydrated (upper) and hydrated (lower) state.  
The surface properties of the clay greatly affect the affinity and thus the binding potential and 
binding mechanism of the drug nanoparticles [29, 30]. In the liquid state, protamine (a cationic 10 
polymer) can easily adsorb to the clay following an ion-exchange process [23, 24, 30], providing it 
with a positively-charged coating. Protamine is rich in arginine which has a basic side chain (pKa of 
12.5), giving the material a positive charge in acidic, neutral and even moderately basic 
environments [31]. The charge reversal of MMT from -26.9 mV to + 14.8 mV upon saturation with 
protamine confirmed successful deposition of the cationic coating onto the clay, Fig. 6.  15 
Although the negatively-charged drug particles were capable of attaching to the un-functionalized 
clay (eg. through hydrophobic interactions between methyl/benzene groups and the siloxane 
surface or through hydrogen bonding with the dangling hydroxyl end groups on MMT [32, 33]), the 
maximum drug loading at which fast dissolution rates were preserved after drying was low. Due to 
charge repulsions, the negatively-charged nanoparticles would strictly avoid the negatively charged 20 
patches on the clay surface, thus limiting the available favourable adsorption sites, Fig. 10c. At 
higher drug loadings, nanoparticles may aggregate at the hydrophobic site, resulting in a loss of 
nanoparticle-induced high surface area and causing a consequential reduction in dissolution rate, 
Fig. 10d. Surface-modification of the negatively-charged clay with the positively-charged PA was 
necessary to introduce favourable charged adsorption sites to the clay surface so that the drug could 25 
attach both through electrostatic and hydrophobic interaction. It is hypothesized that the increase in 
the availability of favourable adsorption sites on the MMT surface allowed a homogenous, 
segregated dispersion of negatively-charged nanoparticles to adsorb to the functionalized carrier, 
based on their fast dissolution rates after drying, Fig. 10a. However, the surface coverage of PA on 
the MMT was also influential in preserving the fast dissolution rate. Overcompensation of the 30 
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surface with positive charge could induce nanoparticle aggregation surrounding positively charged 
patches, which is likely the explanation behind the reduced dissolution rates at high PA coating, Fig. 
10b.  Adsorption of dispersed, fast-dissolving nanoparticles (at >99.5% FF recovery from suspension) 
was achieved by significantly reducing the surface coverage of protamine molecules (Fig. 8b). 
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Fig. 10. Mechanistic description of the potential interactions between the negatively charged drug 
nanoparticles and (A,B) the PA-functionalized and (C,D) the un-functionalized MMT carrier.  
MMT has an expanding 3-layer structure with an interlayer spacing of approx. 1-2 nm [32]. Some 
previous reports have ascribed the adsorption abilities of clays such as montmorillonite for 10 
applications in capturing molecules from solution to its large internal surface (eg. in contamination 
control [30, 34] and drug delivery [24, 32, 35]). In our work however, nanoparticles were first 
precipitated from solution and their relatively large size permitted adsorption only to the external 
surfaces of the PA-MMT carrier. Whether the carrier was present during the drug precipitation step 
or added somewhat later was irrelevant (Fig. 2), as long as nanoparticles were nucleated from 15 
solution and the carrier particles were added before too much growth/aggregation occurred.  
The carrier-mediated approach to nanoparticle stabilization and isolation outlined in this work was 
validated by two drugs, but has generic potential in the preparation and isolation of all negatively-
charged drug nanoparticles. Furthermore, the same rational may be applied to other combinations 
of carriers and polymers for tailored application to any drug substance.  The antisolvent precipitation 20 
technique for nanoparticle preparation, coupled with carrier-mediated isolation by filtration 
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therefore provides an effective means of formulating particles with enhanced dissolution behaviour, 
and could have significant application in formulating BCS Class II drugs. 
 
5. Conclusions 
This work reports a method by which nanoparticles can be isolated into the dried, solid powder form 5 
while retaining dissolution rates which are comparable to or surpass those of the nanoparticles in 
suspension and currently marketed commercial formulations. Negatively-charged nanoparticles 
generated in suspension from a supersaturated solution during an antisolvent precipitation method 
were recovered from suspension using a microparticle carrier system, functionalized with a cationic 
polymer. The drug nanoparticles were stable on the nanoparticle/microparticle composite (at up to 10 
9% drug loading) in suspension for 24 hours without the requirement for the more traditional 
nanosuspension stabilizers. The composites were quickly filterable to produce a dried sample with a 
maintained high drug dissolution rate that stemmed from the nanoparticle size. A more efficient 
isolation was achieved using a polymer-functionalized carrier, as compared to when an un-
functionalized carrier or no carrier was present during filtration. This nanoparticle isolation system 15 
was validated by application to particles of two negatively charged drug substances, fenofibrate and 
mefenamic acid. While success is anticipated for all such drugs, the process has potential to be 
tailored to an even wider range of drug molecules with modification to the nature of the carrier and 
its functionalizing agent.   
 20 
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